News from the web:

Pfizer said Monday that a highly anticipated experimental drug for Alzheimer’s disease, called bapineuzumab, wasn’t effective at slowing memory loss in a large, late-stage clinical trial in patients with a high-risk genetic mutation.

The negative result from this trial, the first of two late-stage trials on bapineuzumab to be announced this year, was expected by many scientists and investors, but it is nonetheless a disappointment to the companies and for the field of Alzheimer’s research.

Read all about it HERE

visit us at AlzheimerHeadlines.com